Diversity in HER2 Expression Among Gynecologic Cancers
Ritu Salani, MD, MBA
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Shubham Pant, MD, MBBS
Significance of HER2 Expression in Solid Tumors
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
Saad Z. Usmani, MD, MBA, FACP
Joshua Richter, MD
Ashley Steinberger, APP
Uncovering New Biomarkers for RCC: A Review of Emerging Techniques
Jody Takemoto, PhD
David Braun
Optimizing HCC Screening: Strategies to Overcome Common Barriers
Hannah Lee, MD
The Potential Impact of RCC Molecular Subtypes on Treatment Outcomes
David Braun, MD, PhD
Precision Strikes in Nuclear Medicine to Treat Prostate Cancer
Munir Ghesani, MD
Enhancing HCC Outcomes Through Multidisciplinary Care
Charles Turck, PharmD, BCPS, BCCCP
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
Jennifer Caudle, DO
Patricia A. Mangan, RN, MSN, APRN-BC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.